România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharos mt ltd. - malta - deferasiroxum - compr. film. - 180mg - alte preparate terapeutice chelatori de fer

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharos mt ltd. - malta - deferasiroxum - compr. film. - 360mg - alte preparate terapeutice chelatori de fer

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharos mt ltd. - malta - deferasiroxum - compr. film. - 90mg - alte preparate terapeutice chelatori de fer

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - sitagliptinum - compr. film. - 100mg - analogi ai glp-1 inhibitori ai dipeptidil peptidazei 4 (dpp-4)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - sitagliptinum - compr. film. - 25mg - analogi ai glp-1 inhibitori ai dipeptidil peptidazei 4 (dpp-4)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - sitagliptinum - compr. film. - 50mg - analogi ai glp-1 inhibitori ai dipeptidil peptidazei 4 (dpp-4)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

heumann pharma gmbh & co. generica kg - germania - nebivololum - compr. - 5mg - agenti betablocanti betablocante selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

walmark, a.s. - republica ceha - naproxenum - compr. - 250mg - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic

Uniunea Europeană - română - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, celule scuamoase - agenți antineoplazici - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofilia a - hemostatice - tratamentul și profilaxia hemoragiei la pacienții cu hemofilie a (deficit congenital de factor viii). acest preparat nu conține factorul von willebrand și este, prin urmare, nu este indicat în boala von willebrand.